Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Teva Plans To Launch Six Biosimilars By 2027
With US Approvals In Hand, Teva And Alvotech Take Aim At Adalimumab And Ustekinumab
May 14 2024
•
By
David Wallace
Teva has outlined plans for six biosimilar launches by 2027 • Source: Shutterstock
More from Biosimilars
More from Products
